البلد: أيرلندا
اللغة: الإنجليزية
المصدر: HPRA (Health Products Regulatory Authority)
URSODEOXYCHOLIC ACID
IPS Healthcare Limited
250 Milligram
Capsules Hard
2011-08-19
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ursofalk 250 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 250mg of ursodeoxycholic acid. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard _Product imported from the UK:_ White, opaque, hard gelatin capsule containing a white compressed powder or granules. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the dissolution of cholesterol gallstones in functioning gallbladders with or without prior extracorporeal shock wave lithotripsy. Primary biliary cirrhosis (PBC) stages I – III. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Ursofalk capsules are for oral administration. The following daily dose is recommended for the various indications: _Primary biliary cirrhosis (PBC) stages I – III:_ The daily dose depends on body weight, and ranges from 3 to 7 capsules (14 ± 2 mg ursodeoxycholic acid per kg of body weight). For the first 3 months of treatment, Ursofalk capsules should be taken divided over the day. With improvement of the liver values the daily dose may be taken once daily in the evening. Body Daily dose Ursofalk capsules weight (kg) (mg/kg BW) FIRST 3 MONTHS subsequently Morning Midday Evening Evening (1 x daily) 47-62 12-16 1 1 1 3 63-78 13-16 1 1 2 4 79-93 13-16 1 2 2 5 94-109 14-16 2 2 2 6 Over 110 2 2 3 7 IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 23/08/2011_ _CRN 2101723_ _page number: 1_ The capsules should be swallowed whole with some liquid. Care should be taken to ensure that they are taken regularly. The use of Ursofalk capsules in primary biliary cirrhosis may be continued indefinitely. In patients with primary biliary cirrhosis, in rare cases th اقرأ الوثيقة كاملة